<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05031832</url>
  </required_header>
  <id_info>
    <org_study_id>MSS344R</org_study_id>
    <nct_id>NCT05031832</nct_id>
  </id_info>
  <brief_title>Chemsex Engagement and HIV Biomedical Prevention in MSM</brief_title>
  <official_title>The Interrelationship Between Chemsex Engagement and HIV Biomedical Prevention in MSM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis&#xD;
      (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be&#xD;
      undermined by the rising HIV transmission risks in men who have sex with men (MSM) who&#xD;
      engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the&#xD;
      HIV epidemic by exploring the complex relationships between chemsex engagement and usage of&#xD;
      HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the&#xD;
      community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive&#xD;
      MSM), for HIV self-testing and completing an electronic questionnaire. The association of&#xD;
      chemsex would be examined between PrEP-na√Øve and PrEP experienced HIV-negative MSM, and&#xD;
      between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects&#xD;
      in case-control analyses using logistic regression and multilevel models. The main outcomes&#xD;
      include coverage of biomedical prevention in MSM, and their drug use patterns.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 4, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>pre-exposure prophylaxis coverage</measure>
    <time_frame>6 months</time_frame>
    <description>proportion of HIV-negative MSM taking pre-exposure prophylaxis; based on self-reported data in questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Good antiretroviral therapy adherence</measure>
    <time_frame>2 years</time_frame>
    <description>proportion of HIV-positive MSM with good antiretroviral therapy adherence; based on self-reported data (CD4 count, viral load level, history of stoppoing ART / missing doses) in questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug use pattern</measure>
    <time_frame>6 months</time_frame>
    <description>types of drugs taken for chemsex engagement (taking before or during sex); based on self-reported data in questionnaire</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Recreational Drug Use</condition>
  <arm_group>
    <arm_group_label>HIV-negative</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-positive</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HIV test</intervention_name>
    <description>HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status</description>
    <arm_group_label>HIV-negative</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        sexually active adult men who have sex with men living in Hong Kong, and able to complete&#xD;
        the questionnaire&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 18 or above&#xD;
&#xD;
          -  male&#xD;
&#xD;
          -  have had sex with men since 2019&#xD;
&#xD;
          -  could be communicated in English or Chinese&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  failed to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong, China</state>
        <zip>0000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Ngai Sze WONG</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Chemsex engagement</keyword>
  <keyword>Pre-exposure prophylaxis</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>men who have sex with men</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

